S
SynaptiCure
Comprehensive ALS care platform integrating specialized neurology and local care coordination for optimized patient outcomes
About SynaptiCure
Synapticure.com is a telehealth startup that provides virtual care for individuals and caregivers dealing with neurodegenerative diseases such as ALS, Alzheimer’s, Huntington's, and Parkinson’s. The company operates in the healthcare market, specifically in the telehealth and neurology sectors.
The business model is centered around providing 24/7 access to neurologists, behavioral health providers, and care coordinators via telehealth. This means patients and caregivers can book appointments and receive care from the comfort of their own homes, without the need to travel to a physical location. This is particularly beneficial for those with mobility issues or who live in remote areas.
Synapticure also offers integrated behavioral health services, recognizing the emotional and psychological challenges that come with neurodegenerative diseases. The company prides itself on being informed by the latest science, helping patients understand their options and access new treatments or enroll in clinical trials.
The company generates revenue through the fees charged for the telehealth services provided. These fees are likely paid by the patients themselves, their insurance companies, or a combination of both.
The co-founders, Brian Wallach and Sandra Abrevaya, have personal experience with ALS, which adds a layer of empathy and understanding to the services provided. The company has received positive reviews for its knowledgeable and empathetic doctors, who are described as being on the cutting edge of neurodegenerative disease treatment.
Source: Dealroom company dataKnowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Nov 2024 | $25M | $100M | RA Capital Management · Rock Health Capital · CVS Health Ventures · GV | ↗ |
| SEEDEquity / VC | Nov 2022 | $0 | — | Rebel Fund | — |
Growth signals
Latest recorded traffic for SynaptiCure is 19K monthly website visits, down 38.7% over the last three months. SynaptiCure's team grew 14% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed15 investors entered at this stage
Y Combinator
GV
Martin Ventures
Lifeforce Capital
Byers Capital
Jeff Huber
Ben Silbermann- GBGerald Bisbee
Rohan Seth
Ron Conway
Joe Kraus
Divya Gugnani- DHDavid Hodgson
Adam M
Rebel Fund
Series A7 investors entered at this stage
B Capital
RA Capital Management
Rock Health Capital
CVS Health Ventures
Optum Ventures
CommonSpirit
Nexus NeuroTech Ventures
Other known investors1 additional known investor
Jonathan Hirsch
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about SynaptiCure on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See SynaptiCure’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







